Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX® (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible ...Middle East

RARITAN, N.J., June 12, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase 3 MAIA (NCT02252172) study showing the addition of DARZALEX® (daratumumab) to lenalidomide and dexamethasone (D-Rd) resulted in a...

Hence then, the article about janssen announces results from phase 3 maia study showing significant overall survival benefits for treatment with darzalex daratumumab in patients with newly diagnosed multiple myeloma who are transplant ineligible was published today ( Saturday 12/06/2021 - 02:30 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX® (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible )

Also on site :

• Woman accused of physically abusing five children at unlicensed daycare in Gates
• Olivia Wilde describes mortifying interaction with Tom Cruise after ‘f–ked up’ custody papers attack
• EU ditching prosperity to become anti-Russian military bloc – Lavrov